Literature DB >> 8978756

The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments.

G V Johnson1, P Seubert, T M Cox, R Motter, J P Brown, D Galasko.   

Abstract

Previous studies have shown that the levels of the microtubule-associated protein tau in the CSF of patients with Alzheimer's disease (AD) are elevated compared with age-matched controls. In spite of these findings, the nature of tau in CSF has not been well documented. In the present study, tau was immunoprecipitated from CSF of patients with AD or acute stroke, as well as normal elderly controls, followed by immunoblot analysis. In all cases, CSF tau consisted primarily of a band migrating at 26-28 kDa. In AD and stroke patients, several smaller tau fragments were also detected. No intact tau was detected in any of the CSF samples examined. Further immunoprecipitation studies showed that the majority of the tau fragments contained the amino terminus of the molecule. Treatment of CSF tau with alkaline phosphatase did not alter the electrophoretic properties of the fragments. These studies clearly demonstrate that CSF tau is truncated rather than intact.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8978756     DOI: 10.1046/j.1471-4159.1997.68010430.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  52 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

2.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

3.  Tau Diagnostics and Clinical Studies.

Authors:  Illana Gozes; Günter Höglinger; James P Quinn; Nigel M Hooper; Kina Höglund
Journal:  J Mol Neurosci       Date:  2017-10       Impact factor: 3.444

4.  A liquid chromatography tandem mass spectroscopy approach for quantification of protein methylation stoichiometry.

Authors:  Grace L Cooper; Carol J Huseby; Claire N Chandler; Jean-Christophe Cocuron; Ana P Alonso; Jeff Kuret
Journal:  Anal Biochem       Date:  2018-03-15       Impact factor: 3.365

Review 5.  Prion-like Spreading in Tauopathies.

Authors:  Jacob I Ayers; Benoit I Giasson; David R Borchelt
Journal:  Biol Psychiatry       Date:  2017-04-13       Impact factor: 13.382

6.  Formation, release, and internalization of stable tau oligomers in cells.

Authors:  Susanne Wegmann; Samantha Nicholls; Shuko Takeda; Zhanyun Fan; Bradley T Hyman
Journal:  J Neurochem       Date:  2016-11-10       Impact factor: 5.372

7.  Propagation of tau pathology in a model of early Alzheimer's disease.

Authors:  Alix de Calignon; Manuela Polydoro; Marc Suárez-Calvet; Christopher William; David H Adamowicz; Kathy J Kopeikina; Rose Pitstick; Naruhiko Sahara; Karen H Ashe; George A Carlson; Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2012-02-23       Impact factor: 17.173

8.  Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.

Authors:  Sudad Saman; WonHee Kim; Mario Raya; Yvonne Visnick; Suhad Miro; Sarmad Saman; Bruce Jackson; Ann C McKee; Victor E Alvarez; Norman C Y Lee; Garth F Hall
Journal:  J Biol Chem       Date:  2011-11-04       Impact factor: 5.157

9.  Multiple mechanisms of extracellular tau spreading in a non-transgenic tauopathy model.

Authors:  Meghan N Le; Wonhee Kim; Sangmook Lee; Ann C McKee; Garth F Hall
Journal:  Am J Neurodegener Dis       Date:  2012-11-25

10.  Aminopeptidases do not directly degrade tau protein.

Authors:  K Martin Chow; Hanjun Guan; Louis B Hersh
Journal:  Mol Neurodegener       Date:  2010-11-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.